FASEB SRC on Lysophospholipd Mediators in Health and Disease

FASEB SRC 关于健康和疾病中的溶血磷脂介质

基本信息

批准号：
8203973
负责人：
JULIE D SABA
金额：
$ 0.4万
依托单位：
FEDERATION OF AMER SOC FOR EXPER BIOLOGY
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-08-12 至 2012-08-11
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8203973
关键词：
Address Affinity American Apoptosis Area Autophagocytosis Basic Science Biochemistry Biological Markers Biological Models Biology Blood Circulation Blood Vessels Brain Breast Calcium Signaling Cardiovascular Diseases Catabolism Cell Cycle Progression Cell Surface Receptors Cell Survival Cellular Stress Response Cellular biology Chemotaxis Clinical Research Clinical Trials Collaborations Colon Colon Carcinoma Communicable Diseases Complement Complex Cytoskeletal Modeling DNA Damage Development Developmental Process Disease Drug resistance Enzymes Epigenetic Process Event Family Family member Functional disorder G-Protein-Coupled Receptors Gene Proteins Genes Genetic Transcription Gonadal structure Growth Health Hematologic Neoplasms Hematopoietic stem cells Histone Acetylation Human Immunology Industry Infection Inflammation Injury International Italy Lipids Lung diseases Lymphocyte Lysophosphatidic Acid Receptors Lysophospholipids Malignant Neoplasms Malignant neoplasm of ovary Mediating Mediator of activation protein Membrane Metabolism Multiple Sclerosis Natural Killer Cells Neurology Nuclear Oncogenes Oral Ovarian Pathway interactions Pharmacology Phospholipids Physiological Physiological Processes Physiology Play Prostate Radiation Injuries Radiation Tolerance Reagent Receptor Gene Receptor Signaling Regulation Research Research Personnel Resort Role SPHK1 enzyme Scientist Signal Transduction Signaling Molecule Societies Sphingolipids Staging Thyroid Gland Tissues Training Transcriptional Regulation Translational Research Tumor Angiogenesis Underrepresented Minority Woman angiogenesis autocrine biological adaptation to stress cancer cell cancer type carcinogenesis career drug sensitivity human disease lysophosphatidic acid malignant ascites malignant breast neoplasm meetings migration novel novel therapeutics paracrine posters prognostic programs radiation resistance receptor response sphingosine 1-phosphate sphingosine kinase symposium therapeutic target trafficking tumor progression

项目摘要

DESCRIPTION (provided by applicant): The 6th FASEB Summer Research Conference on "Lysophospholipid Mediators in Health and Disease" will be held August 14-19, 2011 in Lucca, Italy. This conference will address current concepts in the rapidly developing field of lysphospholipid-mediated signaling and related biology. The lysophospholipids sphingosine- 1-phosphate (S1P) and lysophosphatidic acid (LPA) are bioactive lipids generated via catabolism of membrane sphingolipids (S1P) and phospholipids (LPA). They signal through a family of ubiquitously expressed cell surface receptors, formerly called the Endothelial Differentiation Gene (EDG) receptors. Lysophospholipids mediate a plethora of physiological and pathological activities via interactions with their high-affinity G protein- coupled receptors, as well as through recently revealed receptor-independent intracellular mechanisms. LPA and S1P regulate chemotaxis, stress responses, cytoskeletal organization, calcium signaling, cell survival, apoptosis, autophagy, and gene transcription. Lysophospholipid signaling events also contribute to complex physiological and developmental processes including angiogenesis, lymphocyte trafficking and the migration of hematopoietic stem cells, natural killer cells, and cancer cells. Importantly, lysophospholipids play critical roles in carcinogenesis and cancer progression. Enzymes responsible for catalyzing S1P and LPA formation including autotaxin (the principal enzyme responsible for generating LPA) and sphingosine kinase 1 (which generates S1P) are bona fide oncogenes that promote transformation in model systems, are aberrantly expressed in many human cancers, and serve as biomarkers of prognostic significance. Alterations in lysophospholipid metabolism and signaling also contribute to drug and radiation resistance, tumor angiogenesis, and progression of many cancer types including ovarian, breast, prostate, thyroid, colon, brain and hematological malignancies. Further, recent studies indicate that S1P is a nuclear regulator of epigenetic transcriptional control. Tremendous progress has been made in targeting autotaxin, sphingosine kinase and lysophospholipids themselves as novel therapeutic strategies in cancer. Due to the rapid pace of discovery in this field, this biennial conference is essential to achieving maximal translational potential through cross- pollination of ideas, sharing of new reagents and initiation of collaborations between academic scientists, industry and clinician scientists. Toward that end, our specific aims are to: 1) convene an internationally recognized group of investigators to present and discuss novel findings regarding lysophospholipid metabolism, signaling, regulation, pharmacology and clinical trials; 2) to facilitate participation of early career investigators; 3) to promote participation of women and underrepresented minorities. The program includes oral and poster presentation sessions whose themes cover a range of topics including lysophospholipid biochemistry and signaling, pharmacology, and the role of lysophospholipids in disease. In addition, a new Meet the Experts session will facilitate interactions between early career and established scientists in the field. PUBLIC HEALTH RELEVANCE: This is a proposal to support the convening of the 2011 biannual Federation of American Societies for Experimental Biology Summer Research Conference on Lysophospholipid Mediators in Health and Disease. The meeting will bring together an international group of scientists at all career stages to share the most recent and exciting scientific findings regarding two lipid signaling molecules which share a common family of cell surface receptors through which they modulate cell biology and physiological responses. The effects of lysophospholipid signaling are important in the pathophysiology of cancer, cardiovascular disease, immunology, neurology and infectious disease, and key components of these pathways are being targeted for therapeutic purposes. Women, underrepresented minorities and early stage investigators will play an important role in the conference as speakers, chairs, poster presenters and will have opportunities to interact with others through discussions, Meet the Expert and Meet the Editor sessions.

描述（由申请人提供）：第六届FASEB夏季研究会议“健康与疾病中的溶血磷脂调解人”将于2011年8月14日至19日在意大利卢卡举行。该会议将解决液磷脂介导的信号传导和相关生物学迅速发展领域的当前概念。溶血磷脂1-磷酸（S1P）和溶血磷酸二酸（LPA）是通过膜鞘脂（S1P）和磷脂（LPA）的分解代谢产生的生物活性脂质。它们通过普遍表达的细胞表面受体的家族发出信号，以前称为内皮分化基因（EDG）受体。溶血磷脂通过与其高亲和力G蛋白偶联受体以及最近揭示的受体独立的细胞内机制相互作用，介导了许多生理和病理活性。 LPA和S1P调节趋化性，应激反应，细胞骨架组织，钙信号传导，细胞存活，凋亡，自噬和基因转录。溶物磷脂信号传导事件还有助于复杂的生理和发育过程，包括血管生成，淋巴细胞运输以及造血干细胞，天然杀伤细胞和癌细胞的迁移。重要的是，溶物磷脂在癌变和癌症进展中起关键作用。负责催化S1P和LPA形成的酶，包括自动肝素（负责产生LPA的主要酶）和鞘氨醇激酶1（产生S1P）是促进模型系统中的转化的真正的ONCONES，在许多人类的癌症中都表现出了异常表达，并且是表达的。具有预后意义的生物标志物。溶物磷脂代谢和信号传导的改变也有助于药物和放射性抗药性，肿瘤血管生成以及许多癌症类型的进展，包括卵巢，乳腺癌，前列腺，甲状腺，甲状腺，结肠，大脑和血液学恶性肿瘤。此外，最近的研究表明，S1P是表观遗传转录控制的核调节剂。在靶向自身赛，鞘氨醇激酶和溶血磷脂本身是癌症的新型治疗策略方面，已经取得了巨大进步。由于该领域的发现迅速，这次两年一次的会议对于通过交叉授粉，分享新试剂以及学术科学家，行业和临床科学家之间的合作启动来实现最大的翻译潜力至关重要。为此，我们的具体目的是：1）召集国际认可的研究人员群体，以介绍和讨论有关溶血磷脂代谢，信号传导，调节，药理学和临床试验的新发现； 2）促进早期职业调查人员的参与； 3）促进妇女和代表性不足的少数民族的参与。该计划包括口头和海报演示会议，其主题涵盖了一系列主题，包括溶血磷脂生物化学和信号传导，药理学以及溶物磷脂在疾病中的作用。此外，新的会议专家会议将促进早期职业与该领域的既定科学家之间的互动。公共卫生相关性：这是一项建议，旨在支持2011年美国社会联合会召集实验生物学夏季研究会议，淋summer summer研究会议上关于健康和疾病的溶血磷脂调解人。这次会议将在各个职业阶段汇集一组国际科学家小组，分享有关两个脂质信号分子的最新和令人兴奋的科学发现，它们共享一个共同的细胞表面受体家族，通过它们调节细胞生物学和生理反应。溶血磷脂信号传导的影响在癌症，心血管疾病，免疫学，神经病学和传染病的病理生理学中很重要，这些途径的关键组成部分是针对治疗目的的。妇女，代表性不足的少数族裔和早期调查人员将在会议中发挥重要作用，因为演讲者，主席，海报演示者，并将有机会通过讨论，与专家会面并与编辑会议会面。